EASTONBIOPHARMACEUTICALS(SH:688513) Xin Lang Cai Jing·2025-10-23 03:02Company Overview - Yuandong Biopharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On October 23, Yuandong Biopharmaceutical's stock fell by 5.05%, trading at 50.42 yuan per share, with a total transaction volume of 48.39 million yuan and a turnover rate of 0.53%. The total market capitalization is 8.901 billion yuan [1] Fund Holdings - Huatai-PB Fund has a significant holding in Yuandong Biopharmaceutical, with the Huatai-PB Value Growth Mixed A Fund (460005) holding 418,200 shares, representing 2.45% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.1208 million yuan as of the latest data [2] Fund Manager Information - The fund manager of Huatai-PB Value Growth Mixed A Fund is Fang Wei, who has been in the position for 11 years and 66 days. The total asset size of the fund is 2.127 billion yuan [3] - During Fang Wei's tenure, the best fund return was 260.51%, while the worst return was -17.22% [3]